Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Research & Development: 2018-2024

Historic Research & Development for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $195.2 million.

  • Arcturus Therapeutics Holdings' Research & Development fell 40.55% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year decrease of 30.04%. This contributed to the annual value of $195.2 million for FY2024, which is 1.57% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Research & Development of $195.2 million as of FY2024, which was up 1.57% from $192.1 million recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Research & Development ranged from a high of $195.2 million in FY2024 and a low of $57.8 million during FY2020.
  • Its 3-year average for Research & Development is $178.3 million, with a median of $192.1 million in 2023.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Research & Development soared by 200.38% in 2021, and later declined by 14.97% in 2022.
  • Arcturus Therapeutics Holdings' Research & Development (Yearly) stood at $57.8 million in 2020, then surged by 200.38% to $173.8 million in 2021, then decreased by 14.97% to $147.8 million in 2022, then spiked by 30.04% to $192.1 million in 2023, then increased by 1.57% to $195.2 million in 2024.